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Purpose: Recently, mitochondrial DNA 4977bp deletion (mtDNA4977-mut), a so-
matic mutation related to oxidative stress, has been shown to be associated with 
atrial fibrillation (AF). We hypothesized that patient age, as well as electroanatom-
ical characteristics of fibrillating left atrial (LA), vary depending on the presence 
of mtDNA4977-mut in peripheral blood among patients with non-valvular AF. 
Materials and Methods: Analyzing clinical and electroanatomical characteristics, 
we investigated the presence of the mtDNA4977-mut in peripheral blood of 212 
patients (51.1±13.2 years old, 83.5% male) undergoing catheter ablation for non-
valvular AF, as well as 212 age-matched control subjects. Results: The overall fre-
quency of peripheral blood mtDNA4977-mut in patients with AF and controls was 
not significantly different (24.5% vs. 19.3%, p=0.197). When the AF patient group 
was stratified according to age, mtDNA4977-mut was more common (47.4% vs. 
20.0%, p=0.019) in AF patients older than 65 years than their age-matched con-
trols. Among AF patients, those with mtDNA4977-mut were older (58.1±11.9 
years old vs. 48.8±11.9 years old, p<0.001). AF patients positive for the mtDNA 
mutation had greater LA dimension (p=0.014), higher mitral inflow peak velocity 
(E)/diastolic mitral annular velocity (Em) ratio (p<0.001), as well as lower endo-
cardial voltage (p=0.035), and slower conduction velocity (p=0.048) in the posteri-
or LA than those without the mutation. In multivariate analysis, E/Em ratio was 
found to be significantly associated with the presence of mtDNA4977-mut in pe-
ripheral blood. Conclusion: mtDNA4977-mut, an age-related somatic mutation 
detected in the peripheral blood, is associated with advanced age and electro-ana-
tomical remodeling of the atrium in non-valvular AF.
Key Words:   Atrial fibrillation, mitochondrial DNA, 4977bp deletion mutation, 
atrial remodeling
INTRODUCTION
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia in clinical 
practice and is associated with significant morbidity.1 Many studies have investi-
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GE Vingmed Ultrasound, Horten, Norway) to evaluate pa-
tients for additional structural heart disease, LA remodel-
ing, and ventricular function. The control group consisted 
of 212 healthy subjects without structural heart disease who 
were age-matched with the patient group. We confirmed 
the absence of any potential structural heart disease in the 
control group with echocardiography and treadmill exercise 
ECG. Whole blood samples, collected using EDTA as an 
anticoagulant, were taken for DNA extraction and genetic 
analyses.
Electrophysiological mapping and radiofrequency 
catheter ablation
We conducted electrophysiologic mapping in the AF group. 
For guidance during the RFCA procedure, a 3D electroana-
tomical map was produced. By double trans-septal puncture, 
multi-view pulmonary venograms were obtained. Systemic 
anti-coagulation was achieved with intravenous heparin by 
maintaining an activated clotting time of 350‒400 seconds. 
The 3D spiral CT images were merged with NavX-generated 
3D geometry of the LA and pulmonary veins (PV) (NavX, 
St. Jude Medical Inc., Minnetonka, MN, USA) to acquire 
an electroanatomical map. Also, intracardiac electrograms 
were collected with the Prucka Cardio LabTM electrophysi-
ology system (General Electric Medical Systems Inc., Mil-
waukee, WI, USA). We generated an LA voltage map by 
obtaining contact bipolar electrograms from 350‒500 points 
on the LA endocardium during atrial pacing at 500 ms and 
calculated mean LA voltage as previously described.12,13 To 
calculate local conduction velocity, conduction distance 
was measured on the anterior-posterior and posterior-anteri-
or views of the isochronal map and then divided by the 
time difference as described before.13 In all patients, the 
RFCA was conducted with an open irrigation 3.5 mm-tip 
deflectable catheter (Celsius, Johnson & Johnson Inc., Dia-
mond Bar, CA, USA; Coolflex, St. Jude Medical Inc., Min-
netonka, MN, USA; 30‒35 W; 47°C). All patients initially 
underwent circumferential PV isolation and cavo-tricuspid 
isthmus block. For those patients with PeAF, we added a 
roof line, posterior inferior line, and anterior line14 as a stan-
dard lesion set. At the operator’s discretion, additional abla-
tions of the superior vena cava, a non-PV foci or complex 
fractionated electrogram was conducted. 
Detection of mtDNA4977-mutation in whole blood 
Total DNA was extracted from the whole blood using the 
commercially available QIAamp DNA Mini kit (Qiagen, Va-
gated mechanisms underlying AF development, and grow-
ing evidence supports that genetic variations play a role in 
its pathogenesis.2 For instance, mutations in mitochondrial 
DNA (mtDNA) have been shown to be associated with the 
same factors that are considered critical in development of 
AF: aging process and oxidative stress. So far, a greater 
number of mtDNA mutations have been found in individu-
als with greater age,3 heart failure,4 and ischemic heart dis-
ease.5 Among the known mutations in mtDNA, 4977bp de-
letion mutation (mtDNA4977-mut) is one of the most 
frequently detected genetic alterations,6,7 and it has been 
identified in various human tissues, including skeletal mus-
cle,8 brain,9 and heart.10,11 Fittingly, the mtDNA4977-mut 
has been increasingly associated with AF. While a number 
of studies have been conducted to establish a relationship 
between mtDNA4977-mut and AF, characterizations of AF 
patients positive for this mutation are still inadequate and 
applicability of peripheral mtDNA4977-mut as a biomarker 
in AF remains untested. Therefore, in this study, we set out 
to analyze the frequency of somatic mtDNA4977-mut in 
Korean patients with non-valvular AF and in age-matched 
controls to outline an association between AF and mtD-
NA4977-mut in peripheral blood, to correlate the pathophys-
iological characteristics of AF patients with mtDNA4977-
mut, and finally, to validate the utility of the mutation as a 
biomarker for atrial remodeling.
MATERIALS AND METHODS
Patient selection
The study protocol was approved by the Institutional Re-
view Board of Severance Cardiovascular Hospital, Yonsei 
University Health System, and adhered to the Declaration 
of Helsinki. All patients provided written informed consent. 
The study enrolled 212 consecutive patients with AF in-
cluded in the Yonsei AF Ablation Cohort (83.5% male, 
51.1±12.5 years old) and 212 age-matched controls (50.0% 
male, 51.1±13.2 years old). All AF patients underwent ra-
diofrequency catheter ablation (RFCA). Of the AF patients, 
153 had paroxysmal AF (PAF) and 59 had persistent AF 
(PeAF). We examined all 212 AF patients with 3D spiral 
computed tomography (CT; 64 Channel, Light Speed Vol-
ume CT, Philips, Brilliance 63, Eindhoven, the Nether-
lands) to visually define the anatomy of left atrium (LA), 
and used trans-thoracic echocardiography (Sonos 5500, 
Philips Medical System, Andover, MA, USA or Vivid 7, 
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plasma levels of the following protein markers were mea-
sured using enzyme-linked immunosorbent assay kits: tissue 
inhibitor of metalloproteinases-1 (TIMP-1; R&D Systems, 
Minneapolis, MN, USA), transforming growth factor-β 
(R&D Systems, Minneapolis, MN, USA), and pro-atrial 
natriuretic peptide (pro-ANP; Biomedica, Antony, France).
Statistical analysis
Multiple parameters including clinical features, echocardio-
graphic parameters, electro-anatomical remodeling of the 
LA, and the plasma levels of protein biomarkers were com-
pared between patients with AF and their age-matched con-
trols. These parameters were also compared within the AF 
patient group between those with and without the mtD-
NA4977-mut. Comparisons between groups were analyzed 
using the t-test for continuous variables or the chi-squared 
test for nominal variables. All continuous variables were ex-
pressed as mean±SD, whereas all categorical variables were 
expressed as absolute and relative frequencies (%). In order 
to examine the association between the parameters and 
mtDNA4977-mut in AF, both univariate and multivariate lo-
gistic regression analyses were performed. All statistical 
analyses were conducted using SPSS version 15.0 (SPSS 
Inc., Chicago, IL, USA), and all p-values <0.05 were con-
sidered statistically significant. 
RESULTS
 
Frequency of peripheral mtDNA4977-mut in patients 
with AF vs. control
The somatic mutation associated with oxidative stress mtD-
NA4977-mut was detectable in the peripheral blood of both 
lencia, CA, USA). Two primer sets were designed using 
Primer3 (http://frodo.wi.mit.edu/primer3/), and each forward 
primer was labeled with the fluorescent dye 6-FAM (Macro-
gen Inc., Seoul, Korea) for PCR amplification of mtD-
NA4977-mut (Fig. 1). The primer sequences were as fol-
lows: mtDNA4977bp-Forward 1:5’-FAM-CAGTGAAA 
TGCCCCAACTAAA-3’, mtDNA4977bp-Reverse 1: 
5’-TCGATGATGTGGTCTTTGGA-3’, and mtDNA4977- 
bp-Forward 2:5’-FAM-ATGGCCCACCATAATTACCC-3’, 
mtDNA4977bp-Reverse 2:5’-GATAGGGCTCAGGCG 
TTTGT-3’. PCR amplification was performed with a final 
volume of 10 µL that contained 1.0 µL Gold ST*R buffer 
(Promega, Madison, WI, USA), 1.0 U AmpliTaq Gold 
DNA polymerase (Applied Biosystems, Foster City, CA, 
USA), 0.6 µM of each of the primers, and 10 ng of total 
DNA as the template. Thermal cycling was conducted on a 
PCR machine (Bio-Rad Laboratories, Hercules, CA, USA) 
under the following conditions: 95ºC for 11 min, followed 
by 33 cycles at 94°C for 20 sec, 60°C for 30 sec, and 72°C 
for 30 sec, and a final extension at 72°C for 7 min. After 
PCR had finished, 1.0 µL aliquots of each of the PCR prod-
ucts and 0.2 µL of GeneScan 500 LIZ size standard (Ap-
plied Biosystems, Foster City, CA, USA) were added to 20 
µL de-ionized formamide. The mixture was denaturated 
and separated by capillary electrophoresis on a 3130xI Ge-
netic Analyzer (Applied Biosystems, Foster City, CA, 
USA), and the size and area of the specific fragments were 
displayed as peaks on an electropherogram that was gener-
ated using the GeneScan Analysis Software 3.1.2 (Applied 
Biosystems, Foster City, CA, USA). 
Biochemical analysis
Peripheral blood samples were taken before RFCA and the 
Fig. 1. A schematic representation of the method of mtDNA 4977bp deletion detection. Two different deletion primers (forward and re-
verse sequences, F079-R269 and F109-R308) were used to amplify DNA fragments containing mtDNA4977-mut, ensuring the accuracy of 
PCR amplification and automatic fragment analysis. 
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when they were further broken down according to age (Fig. 
2A). Patients were first divided according to the median 
age of 51 years. Within the AF patient group, the preva-
lence of mtDNA4977-mut was significantly higher in those 
51 years and older (35.5% vs. 12.7%, p<0.001) than in 
those younger than 51 years old. The mutation was still 
more frequent in older AF patients when they were com-
pared to their age-matched controls (35.5% AF vs. 22.7% 
control, p=0.038). These findings were significant when we 
divided the AF patient population between those younger 
than 65 or those older than 65 years old, where the cut-off 
point was suggested by a commonly utilized risk score for 
stroke, CHA2DS2-VASc score (Fig. 2A). Within the AF 
group, AF patients with mtDNA4977-mut were on average 
older (p<0.001), exhibited a higher frequency of diabetes 
AF patients and their age-matched controls. Overall, 21.9% 
(93/424) of patients included in the study tested positive for 
mtDNA4977-mut. When AF patients were compared to the 
control group, the prevalence of peripheral mtDNA4977-
mut was not significantly different overall (24.5% for AF 
vs. 19.3% for control, p=0.197). As further outlined in Ta-
ble 1, body mass index (p=0.003), frequency of hyperten-
sion (p=0.007), and LA dimension (p<0.001) were all 
greater and left ventricular ejection fraction (p=0.001) was 
smaller in AF patients than their age-matched controls. 
Peripheral mtDNA4977-mut in AF
While the AF and control groups overall did not show sig-
nificant differences in the frequency of mtDNA4977-mut in 
peripheral blood, the two groups did significantly differ 
Table 1. Baseline Characteristics of Patients with AF and Their Age-Matched Controls
AF (n=212) Control (n=212) p value
Age, yrs   51.1±12.5   51.1±13.2   0.991
PAF, n (%) 153 (72.2)   0 (0.0) -
BMI, kg/m2 25.3±3.6 23.8±2.9   0.003
CHF, n (%) 11 (5.2)   0 (0.0) -
Hypertension, n (%)   77 (36.3) 21 (9.9)   0.007
DM, n (%) 19 (9.0)   9 (4.2)   0.999
Stroke, n (%)   24 (11.3)   0 (0.0) -
TIA, n (%)   9 (4.2)   0 (0.0) -
CHADS2 score   0.7±0.9 - -
mtDNA4977 -mut, n (%)   52 (24.5)   41 (19.3)   0.197
TTE: 2D and Doppler parameters
    LA size, mm 40.7±5.6 34.6±4.8 <0.001
    LVEF, % 62.6±7.3 66.2±7.2   0.001
    E/Em   9.5±4.0   9.1±4.2   0.228
AF, atrial fibrillation; PAF, paroxysmal AF; BMI, body mass index; CHF, congestive heart failure; DM, diabetes mellitus; TIA, transient ischemic attack; mtD-
NA4977-mut, mitochondrial DNA 4977bp deletion mutation; TTE, trans-thoracic echocardiography; LA, left atrium; LVEF, left ventricular ejection fraction; E, 
mitral inflow early diastolic velocity; Em, mitral annulus early diastolic velocity.
Fig. 2. Comparison of the frequency of mtDNA4977-mut in AF and control groups, each of which is divided according to the ages of 51 (median value) and 65 
years (depending on CHA2DS2-VASc score) (A), and representative color-coded 3D voltage map of LA (B). Mean LA voltage is higher in patients without mtD-
NA4977-mut (upper panel) than in those with mtDNA4977-mut (lower panel). AF, atrial fibrillation; LA, left atrium.
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1.225, p=0.029] was found to be independently associated 
with mtDNA4977-mut (Table 3). In protein biomarker assay, 
plasma levels of TIMP-1 (p=0.004) and pro-ANP (p=0.036) 
were higher in AF patients with mtDNA4977-mut than those 
without the mutation (Table 2), and TIMP-1 was indepen-
dently associated with mtDNA4977-mut in patients with 
AF (OR 1.896, 95% CI 1.094‒3.284, p=0.023) (Table 3). 
However, clinical recurrence rates after AF catheter abla-
tion were not significantly different between patients with 
and without mtDNA4977-mut (Fig. 3).
DISCUSSION
In the current study, we reported that a somatic mutation, 
mtDNA4977-mut, detected in peripheral blood is associated 
with AF, the presence of which varied depending on age. 
(p=0.008), and were more likely to take angiotensin con-
verting enzyme inhibitor/angiotensin II receptor blocker 
(p=0.007) or statin (p=0.001) than those without mtD-
NA4977-mut (Table 2).
mtDNA497-mut and electro-anatomical remodeling of 
the left atrium
Table 2 shows comparisons of electroanatomical character-
istics between AF patients with and without mtDNA4977-
mut. Patients with mtDNA4977-mut had a greater LA size 
(p=0.014) and higher mitral inflow peak velocity (E)/diastol-
ic mitral annular velocity (Em) ratio (p<0.001) than those 
without the mutation. Endocardial voltage (p=0.035) as well 
as conduction velocity (p=0.048) on the posterior LA were 
lower in patients possessing the somatic mutation (Fig. 2B). 
Upon multivariate logistic regression analysis, E/Em ratio 
[odds ratio (OR) 1.113, 95% confidence interval (CI) 1.011‒ 
Table 2. Comparison of Electroanatomical Phenotypes between AF Patients with and without the mtDNA4977 - Deletion Mu-
tation
mtDNA4977 -mut (+) (n=52) mtDNA4977 -mut (-) (n=160) p value
Age, yrs   58.1±11.9   48.8±11.9 <0.001
Paroxysmal AF, n (%) 38 (73.1) 115 (71.9) 0.434 
BMI, kg/m2 25.1±5.4 25.3±2.8 0.354 
Heart failure, n (%) 2 (3.9)   9 (5.6) 0.309 
Hypertension, n (%) 23 (44.2)   54 (33.8) 0.087 
Diabetes, n (%)   9 (17.3) 10 (6.3) 0.008 
Stroke, n (%) 2 (3.9)   22 (13.8) 0.091 
TIA, n (%) 4 (7.7)   5 (3.1) 0.155 
CHADS2 score   0.8±1.0   0.6±0.9 0.262 
Medication
    ACE inhibitor/ARB, n (%) 22 (42.0)   39 (24.1) 0.007 
    Statin, n (%) 15 (28.0) 15 (9.4) 0.001 
TTE: 2D and Doppler parameters
    LA size, mm 42.2±5.4 40.2±5.6 0.014 
    LVEF, % 62.5±7.3 62.7±7.3 0.454 
    E/Em 11.4±5.2   8.9±3.3 <0.001
LA voltage
    Anterior LA, mV   1.1±0.6   1.1±0.6 0.485 
    Posterior LA, mV   0.8±0.6   1.2±1.0 0.035 
    LA appendage, mV   2.5±1.5   2.5±1.4 0.473 
Conduction velocity
    Anterior LA, m/sec   0.6±0.2   0.7±0.3 0.201 
    Posterior LA, m/sec   0.6±0.3   0.7±0.3 0.048 
Biomarkers
    TIMP-1, ng/mL   1.5±0.8   1.2±0.5 0.004 
    Pro-ANP, nmol/L   2.7±2.7   2.0±2.1 0.036 
    TGF-β, ng/mL 13.3±9.9 13.7±9.7 0.404 
BMI, body mass index; TIA, transient ischemic attack; LVEF, left ventricular ejection fraction; E, mitral inflow peak velocity; Em, diastolic mitral annular 
velocity; ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; TIMP-1, tissue inhibitor of metalloproteinase-1; pro-
ANP, pro-atrial natriuretic peptide; TGF-β, transforming growth factor-β; AF, atrial fibrillation; LA, left atrium.
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tween peripheral blood mtDNA4977-mut, AF, and remodel-
ing, suggesting the potential applicability of the mtDNA 
mutation as a biomarker of cardiac arrhythmia.
AF is a degenerative disease and is related to 
mtDNA4977bp deletion mutation
AF is now commonly recognized as a disease of aging; ad-
vanced age increases one’s predisposition to this arrhythmia. 
According to recent studies, the mechanism underlying aging 
is primarily a progressive decline in mitochondrial function.15 
Leakage of superoxide from the mitochondrial electron 
transport chain induces oxidative damage and accumulation 
of damage over time results in mtDNA deletion.16,17 mtD-
NA4977-mut is one of the most common deletion muta-
tions identified in mitochondria. This mutation is frequently 
found in aging human tissues, especially those vulnerable to 
increased oxidative stress, like the heart.18,19 In the mutation, 
deletion of a sequence that encodes subunits of ATPase and 
NADH dehydrogenase disrupts aerobic metabolism and ul-
timately generates increased amounts of radical oxidative 
stress (ROS).11,20 Similarly, many studies attempting to re-
Additionally, peripheral mtDNA4977-mut was associated 
with advanced electro-anatomical remodeling of the LA, el-
evated left ventricular filling pressure estimated by E/Em, 
and high plasma levels of TIMP-1. To the best of our knowl-
edge, our study is first to demonstrate an association be-
Table 3. Association between Clinical Parameters and mtDNA4977-mut in AF Using a Logistic Regression Model 
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age ≥65, n (%) 3.706 1.770‒7.758 0.001 1.767 0.731‒4.272 0.206
BMI, kg/m2 0.974 0.885‒1.073 0.598
Heart failure, n (%) 0.671 0.140‒3.210 0.617
Hypertension, n (%) 1.557 0.823‒2.946 0.174
Diabetes, n (%) 3.119 1.191‒8.164 0.021 1.036 0.967‒1.110 0.313
Stroke, n (%) 0.266 0.033‒2.108 0.210
TIA, n (%) 2.093   0.340‒12.885 0.426
CHADS2 score 1.193 0.863‒1.650 0.286
TTE: 2D and Doppler parameters
    LA size, mm 1.066 1.006‒1.129 0.030 1.036 0.967‒1.110 0.313
    LVEF, % 0.997 0.955‒1.041 0.900
    E/Em 1.154 1.061‒1.255 0.001 1.113 1.011‒1.225 0.029
LA voltage
    Mean LA, mV 0.772 0.443‒1.346 0.362
    LA appendage, mV 1.006 0.780‒1.297 0.964
Conduction velocity
    Anterior, m/sec 1.237 0.534‒2.865 0.620
    Posterior, m/sec 0.668 0.314‒1.421 0.295
Biomarkers
    TIMP-1, ng/mL 1.838 1.112‒3.039 0.018 1.896 1.094‒3.284 0.023
    Pro-ANP, nmol/L 1.129 0.982‒1.299 0.089
    TGF-β, ng/mL 0.995 0.962‒1.030 0.795
OR, odds ratio; CI, confidence interval; BMI, body mass index; TIA, transient ischemic attack; TTE, trans-thoracic echocardiography; LA, left atrium; LVEF, 
left ventricular ejection fraction; E, mitral inflow peak velocity; Em, diastolic mitral annular velocity; TIMP-1, tissue inhibitor of metalloproteinase-1; pro-
ANP, pro-atrial natriuretic peptide; TGF-β, transforming growth factor-β; AF, atrial fibrillation.
Fig. 3. A Kaplan-Meier curve comparing recurrence rates after radiofre-
quency catheter ablation for AF between patients with and without mtD-
NA4977-mut. AF, atrial fibrillation.
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tation in AF. From our analysis, we speculated that higher 
LV filling pressure indicated by higher E/Em evoked more 
advanced structural remodeling of LA in compensation.33-35 
We previously reported that impaired LV diastolic function 
significantly contributed to electroanatomical remodeling 
of LA in patients with PAF.36 In the current study, this inter-
action between the two chambers was especially prominent 
in AF patients with the mtDNA mutation. When we com-
pared AF types, mtDNA4977-mut was present in 24.8% of 
PAF patients and in 24.1% of PeAF patients (p=0.867). 
This suggests that mtDNA4977-mut is more likely to be as-
sociated with ageing, metabolic factors, ventricular diastol-
ic dysfunction, or left atrial remodeling, rather than AF bur-
den itself.
Clinical implications
Over time, surrogate markers have gained increasing clini-
cal importance, as detection allows for not only early diag-
nosis of a disease but also prognosis. This is especially true 
in chronic degenerative diseases like AF. Several protein 
biomarkers have been shown to reflect various aspects of 
AF, such as electro-anatomical remodeling37 or chronicity.38 
However, multiple confounding factors, such as transient 
inflammation and associated systemic disease, affect plas-
ma levels of these protein biomarkers and ultimately pre-
vent effective and accurate use in the clinic. In contrast to 
protein biomarkers, genetic markers are reproducible and 
stable enough to characterize the state of disease in patients 
with greater certainty. As our study showed, mtDNA4977-
mut may serve as a stable indicator of patients with AF or at 
risk of rapid remodeling of the LA due to AF. Furthermore, 
the results of the current study suggest the potential utility 
of peripheral blood for the detection of mtDNA4977-mut in 
cardiac disease or arrhythmias. Previous studies on the asso-
ciation between mtDNA mutation and AF have been con-
ducted by acquiring atrial tissue for analysis,10,11 which is 
clinically impractical. As these results have been repro-
duced in our study with peripheral blood, we demonstrated 
that mtDNA mutation can be readily assessed as a valuable 
biomarker of AF; further studies are need to confirm our re-
sults in different populations. 
Limitations
We analyzed mtDNA4977-mut in a Korean population, and 
this study was a observational study that included a highly-
selected group of patients referred from the Yonsei AF Ab-
lation Cohort. The small number of patients in each group 
veal the pathophysiology of AF have pointed to mitochon-
drial dysfunction and ROS as important mediators thereof: 
for example, NADPH oxidase,21,22 NOS,23,24 and MPO,25,26 
previously discovered as major sources of ROS in the heart,27 
have now been shown to be critical in arrhythmogenesis. 
Furthermore, a growing body of evidence supports the idea 
that mitochondrial dysfunction can directly alter cardio-
myocyte excitability and cell-to-cell coupling.28-30 As aging 
and AF exhibit surprising similarities, subsequent studies 
have attempted to investigate whether there indeed exists 
an association between aging, mitochondrial dysfunction, 
and AF. Lai, et al.10 examined right atrial appendage tissues 
and found that both aging and AF were independently asso-
ciated with accumulation of mtDNA4977-mut. Lin, et al.,11 
also observed increased oxidative damage, including the 
mtDNA deletion mutation, in atrial muscles from fibrillat-
ing hearts in comparison to tissue in sinus rhythm. Howev-
er, whether ROS and mitochondrial dysfunction as result of 
the ageing process alone are sufficient to produce an ar-
rhythmogenic atrial substrate remain in question.15 In our 
study, we observed that among AF patients, those with the 
mtDNA mutation were older on average. In comparison to 
their age-matched controls, elderly AF patients still main-
tained a higher prevalence of mtDNA4977-mut. 
Electroanatomical remodeling and diastolic dysfunction 
in mtDNA4977-mut
Over the course of AF, the presence of mtDNA4977-mut 
was associated with more accelerated electroanatomical re-
modeling. Our current study revealed that parameters re-
flecting electroanatomical remodeling, such as atrial voltage 
and conduction velocity, are significantly different between 
patients with and without the mtDNA4977-mut. In line with 
our results, Tsuboi, et al.31 postulated that a rapid atrial rate 
or AF induced hypoxia in the atrium, increasing the genera-
tion of oxygen radicals. Further deterioration of mitochon-
drial function ensued as damage to mtDNA accumulated. 
The level of ATP in atrial muscle subsequently fell, result-
ing in impaired calcium handling, increased calcium in the 
cytoplasm, and reduced L-type calcium current.31 Ultimate-
ly, atria were electrically remodeled, beginning a vicious 
cycle in which AF begets AF.32 In addition to electrical re-
modeling, mtDNA4977-mut appears to be also associated 
with structural remodeling of the LA in AF. E/Em ratio and 
LA size, according to our observation, were significantly el-
evated in the mtDNA4977-mut positive AF patient group, 
and E/Em ratio was independently associated with the mu-
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19. Fukagawa NK, Li M, Liang P, Russell JC, Sobel BE, Absher PM. 
Aging and high concentrations of glucose potentiate injury to mi-
tochondrial DNA. Free Radic Biol Med 1999;27:1437-43.
20. Wei YH, Lee HC. Oxidative stress, mitochondrial DNA mutation, 
and impairment of antioxidant enzymes in aging. Exp Biol Med 
(Maywood) 2002;227:671-82.
21. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Chan-
non KM, et al. Atrial sources of reactive oxygen species vary with 
the duration and substrate of atrial fibrillation: implications for the 
antiarrhythmic effect of statins. Circulation 2011;124:1107-17.
22. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatun-
ga C, et al. A myocardial Nox2 containing NAD(P)H oxidase 
contributes to oxidative stress in human atrial fibrillation. Circ Res 
2005;97:629-36.
23. Nishijima Y, Sridhar A, Bonilla I, Velayutham M, Khan M, Teren-
tyeva R, et al. Tetrahydrobiopterin depletion and NOS2 uncou-
pling contribute to heart failure-induced alterations in atrial elec-
trophysiology. Cardiovasc Res 2011;91:71-9.
24. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Predni-
sone prevents atrial fibrillation promotion by atrial tachycardia re-
modeling in dogs. Cardiovasc Res 2006;69:865-75.
25. Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, 
Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic 
mediator of atrial fibrillation. Nat Med 2010;16:470-4. 
26. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx 
M, et al. Markers of oxidative stress after ablation of atrial fibrilla-
tion are associated with inflammation, delivered radiofrequency 
energy and early recurrence of atrial fibrillation. Clin Res Cardiol 
2012;101:217-25.
27. Bonilla IM, Sridhar A, Györke S, Cardounel AJ, Carnes CA. Nitric 
oxide synthases and atrial fibrillation. Front Physiol 2012;3:105.
28. Yoshida H, Bao L, Kefaloyianni E, Taskin E, Okorie U, Hong M, 
et al. AMP-activated protein kinase connects cellular energy me-
tabolism to KATP channel function. J Mol Cell Cardiol 2012;52: 
410-8.
may have affected our analysis. 
Conclusion
mtDNA4977-mut, an oxidative stress-related somatic muta-
tion in mitochondrial DNA detected in peripheral blood, 
was associated with older age and a greater degree of elec-
tro-anatomical remodeling of the LA in patients with non-
valvular atrial fibrillation. 
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